Kymriah 1.2 × 10 6 – 6 × 108 cells dispersion for infusion

  • DHPC
Company
Novartis Ireland Limited
Active Ingredient
Strength
  • 1.2
Dosage Form
Dispersion for infusion
Legal Category
A - prescription, may not be renewed
Last Updated
25/09/2026

Direct Healthcare Professional Communications

  • DHPC - Risk of secondary malignancy of T-cell origin in CD19- or BCMA-directed CAR T-cell therapies

    Direct Healthcare Professional Communication (DHPC)

    PDF627.68 KB

Novartis Ireland Limited

Vista Building, Elm Park Business Park, Merrion Road, Dublin 4, Ireland, Dublin

Email
medinfo.dublin@novartis.com